Sun Pharma’s India growth and launches offset US generics weakness in Q1FY27

Sun Pharma reported 10% year-on-year consolidated revenue growth in Q1FY27, driven by a 16% rise in India formulations revenue and five domestic product launches. Innovative medicines and emerging markets also grew, while US formulations fell 9.7%. Its Organon acquisition is expected to close in Q4FY27.

— Source publishedTue, 4 Aug, 2026, 16:03 IST·First seen Tue, 4 Aug, 2026, 16:10 IST·Source Mint · Markets

What happened

Sun Pharmaceutical Industries · Sun Pharma’s Q1FY27 revenue rose 10%, led by 16% growth in India formulations and five domestic launches, including generic

Key facts

  • Consolidated revenue: ₹15,183 crore, up 10% YoY
  • India formulations revenue: ₹5,475 crore, up 16% YoY; 36% of consolidated revenue
  • Five products launched in India during Q1
  • Innovative medicines revenue: $351 million, up 12.8% YoY; 21.9% of sales
  • Emerging markets revenue: ₹2,945 crore, up 15.4% YoY; 19.4% of sales
  • US formulations revenue: $427 million, down 9.7% YoY
  • EBITDA margin: 28.1%, down 133 basis points YoY
  • Gross margin: 80.5%, up 95 basis points YoY
  • Organon acquisition expected to close in Q4FY27
  • Annual free cash flow expected to double by FY29
  • Share price reached ₹2,046.90; valuation at 35.5x FY27 estimated earnings

Why this matters

The planned Organon acquisition, expected to close in Q4FY27, offers Sun Pharma a potentially meaningful platform to expand its portfolio and diversify beyond US generics.

What to watch

  • Whether India formulations growth remains above 12-15% and new launches gain meaningful prescription share.
  • Sequential trend in US formulations revenue, including price erosion, new approvals and base-business stabilization.
  • Innovative medicines growth, especially specialty product adoption and geographic expansion.
  • Organon deal closing timeline in Q4FY27, purchase financing, regulatory approvals and stated synergy targets.
  • Gross-margin movement, R&D and sales-and-marketing intensity, and any increase in leverage after the acquisition.
  • Accelerate domestic launches in chronic, specialty and high-prescription therapy areas to defend India growth above the industry rate.
  • Prioritize US portfolio rationalization, complex generics and higher-value specialty products rather than volume-led commodity launches.
  • Prepare Organon integration plans for portfolio overlap, supply-chain synergies, sales-force deployment and debt reduction.
  • Use strong India cash generation to fund launch investments and limit acquisition-related balance-sheet stress.